Clinical effect and future considerations for molecularly-targeted therapy in renal cell carcinoma

Area of Science:

• Oncology
• Molecular Biology
• Nephrology

Background:

• Vascular endothelial growth factor (VEGF) pathway activation is crucial for the angiogenic phenotype observed in renal cell carcinoma (RCC).
• Targeting the VEGF pathway has become a cornerstone of treatment strategies for metastatic RCC.
• Several therapeutic agents have demonstrated significant clinical efficacy in managing advanced stages of this disease.

Purpose of the Study:

• To review current therapeutic strategies targeting the VEGF pathway in metastatic renal cell carcinoma.
• To discuss the clinical activity of agents like bevacizumab, sunitinib, sorafenib, and temsirolimus.
• To highlight emerging clinical considerations including treatment resistance, response assessment, and combination therapies.

Main Methods:

• Review of clinical trials and therapeutic guidelines.
• Analysis of pharmacological mechanisms of action for key agents.
• Synthesis of data on clinical outcomes and resistance patterns.

Main Results:

• Bevacizumab (VEGF ligand-binding antibody) exhibits substantial clinical activity.
• Sunitinib and sorafenib (VEGF receptor small molecule inhibitors) are effective in metastatic RCC.
• Temsirolimus (mTOR inhibitor) also demonstrates significant clinical benefit.

Conclusions:

• VEGF pathway inhibitors and mTOR inhibitors are established treatments for metastatic RCC.
• Understanding and overcoming treatment resistance is a critical area for future research.
• Optimizing response measurement and exploring combination therapies are key to improving patient outcomes.